175 related articles for article (PubMed ID: 38486026)
21. IFI6 depletion inhibits esophageal squamous cell carcinoma progression through reactive oxygen species accumulation via mitochondrial dysfunction and endoplasmic reticulum stress.
Liu Z; Gu S; Lu T; Wu K; Li L; Dong C; Zhou Y
J Exp Clin Cancer Res; 2020 Jul; 39(1):144. PubMed ID: 32727517
[TBL] [Abstract][Full Text] [Related]
22. Identification and validation of an autophagy-related gene signature for predicting prognosis in patients with esophageal squamous cell carcinoma.
Shi X; Li Y; Pan S; Liu X; Ke Y; Guo W; Wang Y; Ruan Q; Zhang X; Ma H
Sci Rep; 2022 Feb; 12(1):1960. PubMed ID: 35121801
[TBL] [Abstract][Full Text] [Related]
23. Loss of FBP1 promotes proliferation, migration, and invasion by regulating fatty acid metabolism in esophageal squamous cell carcinoma.
He Y; Hua R; Li B; Gu H; Sun Y; Li Z
Aging (Albany NY); 2020 Nov; 13(4):4986-4998. PubMed ID: 33232284
[TBL] [Abstract][Full Text] [Related]
24. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
[TBL] [Abstract][Full Text] [Related]
25. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
[TBL] [Abstract][Full Text] [Related]
26. Tissue-based metabolomics reveals metabolic biomarkers and potential therapeutic targets for esophageal squamous cell carcinoma.
Chen Z; Gao Y; Huang X; Yao Y; Chen K; Zeng S; Mao W
J Pharm Biomed Anal; 2021 Apr; 197():113937. PubMed ID: 33609949
[TBL] [Abstract][Full Text] [Related]
27. Minichromosome maintenance 6 complex component identified by bioinformatics analysis and experimental validation in esophageal squamous cell carcinoma.
Li X; Ren Z; Xiong C; Geng J; Li Y; Liu C; Ren C; Liu H
Oncol Rep; 2020 Sep; 44(3):987-1002. PubMed ID: 32583000
[TBL] [Abstract][Full Text] [Related]
28. Role of deubiquitinase JOSD2 in the pathogenesis of esophageal squamous cell carcinoma.
Wang WP; Shi D; Yun D; Hu J; Wang JF; Liu J; Yang YP; Li MR; Wang JF; Kong DL
World J Gastroenterol; 2024 Feb; 30(6):565-578. PubMed ID: 38463028
[TBL] [Abstract][Full Text] [Related]
29. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
Lu Y; Wang W; Wang F
Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
[TBL] [Abstract][Full Text] [Related]
30. Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma.
Zhao S; Hu X; Zhou P; Li A; Chen L; Wang D; He J; Jiang Y
Cancer Biol Ther; 2023 Dec; 24(1):2256927. PubMed ID: 38032149
[TBL] [Abstract][Full Text] [Related]
31. Exosomal PIK3CB promotes PD-L1 expression and malignant transformation in esophageal squamous cell carcinoma.
Xu W; Chen Y; Zhang Z; Jiang Y; Wang Z
Med Oncol; 2023 Jul; 40(8):221. PubMed ID: 37402056
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma.
Zuo J; Zhao M; Fan Z; Liu B; Wang Y; Li Y; Lv P; Xing L; Zhang X; Shen H
Thorac Cancer; 2020 Mar; 11(3):738-747. PubMed ID: 32012470
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma.
Guo W; Zhang F; Shao F; Wang P; Li Z; Yang X; He Z; Shi S; Gao Y; He J
Hum Pathol; 2019 Feb; 84():291-298. PubMed ID: 30296523
[TBL] [Abstract][Full Text] [Related]
34. Plasma free amino acid profiling of esophageal cancer using high-performance liquid chromatography spectroscopy.
Ma H; Hasim A; Mamtimin B; Kong B; Zhang HP; Sheyhidin I
World J Gastroenterol; 2014 Jul; 20(26):8653-9. PubMed ID: 25024622
[TBL] [Abstract][Full Text] [Related]
35. Roles of the hexosamine biosynthetic pathway and pentose phosphate pathway in bile acid-induced cancer development.
Munemoto M; Mukaisho KI; Miyashita T; Oyama K; Haba Y; Okamoto K; Kinoshita J; Ninomiya I; Fushida S; Taniura N; Sugihara H; Fujimura T
Cancer Sci; 2019 Aug; 110(8):2408-2420. PubMed ID: 31215094
[TBL] [Abstract][Full Text] [Related]
36. The Molecular Characterization of Genetic Abnormalities in Esophageal Squamous Cell Carcinoma May Foster the Development of Targeted Therapies.
Testa U; Castelli G; Pelosi E
Curr Oncol; 2023 Jan; 30(1):610-640. PubMed ID: 36661697
[TBL] [Abstract][Full Text] [Related]
37. Overexpressed COL3A1 has prognostic value in human esophageal squamous cell carcinoma and promotes the aggressiveness of esophageal squamous cell carcinoma by activating the NF-κB pathway.
Zhou J; Yang Y; Zhang H; Luan S; Xiao X; Li X; Fang P; Shang Q; Chen L; Zeng X; Yuan Y
Biochem Biophys Res Commun; 2022 Jul; 613():193-200. PubMed ID: 35598375
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance and function of the vacuolar H+-ATPase subunit V1E1 in esophageal squamous cell carcinoma.
Son SW; Kim SH; Moon EY; Kim DH; Pyo S; Um SH
Oncotarget; 2016 Aug; 7(31):49334-49348. PubMed ID: 27384996
[TBL] [Abstract][Full Text] [Related]
39. Mitochondrial pyruvate carrier function is negatively linked to Warburg phenotype in vitro and malignant features in esophageal squamous cell carcinomas.
Li Y; Li X; Kan Q; Zhang M; Li X; Xu R; Wang J; Yu D; Goscinski MA; Wen JG; Nesland JM; Suo Z
Oncotarget; 2017 Jan; 8(1):1058-1073. PubMed ID: 27911865
[TBL] [Abstract][Full Text] [Related]
40. Analysis of immunotherapeutic response-related signatures in esophageal squamous-cell carcinoma.
Zheng B; Li J; Zhang M; Zhang P; Deng W; Pu Y
Front Immunol; 2023; 14():1117658. PubMed ID: 36817484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
